- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05224986
Patrones de estilo de vida y control glucémico
The goal of the proposed study is to evaluate the feasibility and initial efficacy of stabilizing lifestyle behaviors to improve glucose control and body composition in patients with pre-diabetes.
The investigator proposes that following stable lifestyle behaviors will improve patients' glucose control, body composition, and liver fat. The results from this study has the potential to impact clinical practice and patient care.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Variability in lifestyle behaviors has been associated with adverse health, specifically poor glucose control. The project proposes to test whether reducing this variability improves glycemia in patients with pre-diabetes. If successful, this simple positive lifestyle message to keep stable behaviors has the potential to improve the health of millions of adults worldwide.
This project will enroll participants with pre-diabetes who have erratic lifestyle behaviors and randomize them to either maintain their usual habits (control group) or stabilize their behaviors (stability group). Both groups will be followed for 12 weeks. Before the start of the 12-week period, all participants will track their sleep for 2 weeks and will wear a glucose monitor to measure their glucose levels. At the start and end of the 12-week period, they will come to the research lab to undergo a glucose tolerance test. This test will measure how their body reacts to a glucose load. They will also undergo magnetic resonance imaging and spectroscopy scanning. This scan will provide information on body composition and liver fat content.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
New York
-
New York, New York, Estados Unidos, 10032
- Columbia University Irving Medical Center
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Pre-diabetic kg/m2 (hemoglobin A1c 5.7-6.9%)
- 25 years or older
- BMI between 25-39.9 kg/m2
- Sleep duration ≥6 hours a night assessed with wrist actigraphy (for 14 nights)
- Variable bedtime, SD≥45 minutes.
Exclusion Criteria:
- Chronic Kidney Disease (GFR<60)
- Uncontrolled hypertension (≥160/100 mmHg)
- Obstructive Sleep Apnea
- Psychiatric or neurological disorder
- Prevalent cardiovascular disease
- Dyslipidemia (triglycerides≥200 mg/dL)
- Medications that affect insulin sensitivity, glucose concentrations, and body weight
- Non-day or rotating shift workers
- Travel across time zones
- Active participation in weight loss program or within past 3 months
- Current or past alcohol/drug abuse
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Cuidados de apoyo
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Sin intervención: Variable Schedule
Participants randomized to Variable Schedule (VS) will be asked to maintain their usual habits for 12 weeks. |
|
|
Experimental: Fixed Schedule
Participants randomized to Fixed Schedule (FS) will be asked to stabilize their lifestyle behaviors for 12 weeks. |
Participants will be asked to maintain a fixed schedule for 12 weeks. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adipose Tissue Measurement - Total
Periodo de tiempo: 12 weeks
|
Measuring total adiposity. Measured by MRI, includes both subcutaneous and visceral adipose tissue. |
12 weeks
|
|
Adipose Tissue Measurement - Subcutaneous
Periodo de tiempo: 12 weeks
|
Measurement of subcutaneous adiposity using MRI. |
12 weeks
|
|
Adipose Tissue Measurement - Visceral
Periodo de tiempo: 12 weeks
|
Measurement of visceral adiposity using MRI. |
12 weeks
|
|
Glucose Area Under Curve
Periodo de tiempo: 12 weeks
|
Testing glycemic control.The primary outcome variable is glucose under the curve during the oral glucose tolerance test. |
12 weeks
|
|
Mean Amplitude of Glycemic Excursion and Standard Deviation of Mean Glucose
Periodo de tiempo: 12 weeks
|
Testing glucose variability. The primary outcome variables are mean amplitude of glucose excursion and standard deviation of average glucose. |
12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Liver Fat Content
Periodo de tiempo: 12 weeks
|
This is to assess liver fat measured by MRS and MRI in %. |
12 weeks
|
|
Disposition Index
Periodo de tiempo: 12 weeks
|
This is to assess disposition index, measured using HOMA-IR. The disposition index is the product of the insulogenic index and homeostatic model of assessment for insulin resistance. |
12 weeks
|
|
Short-term Change in Glycemia
Periodo de tiempo: Baseline, up to 12 weeks
|
Assessing whether short-term glycemia is changed by measuring fructosamine using two-sample t-tests. |
Baseline, up to 12 weeks
|
|
Endothelial cell inflammation (sub-set, n≤10)
Periodo de tiempo: Baseline, 12 weeks
|
NF-κB nuclear fluorescence area for pilot study. |
Baseline, 12 weeks
|
|
White blood cells
Periodo de tiempo: Baseline, 12 weeks
|
Leukocytes and neutrophils |
Baseline, 12 weeks
|
|
Long-term Change in Glycemia
Periodo de tiempo: Baseline, 12 weeks
|
Assessing whether long-term glycemia is changed by measuring hemoglobin A1c using two-sample t-tests. |
Baseline, 12 weeks
|
|
Endothelial cell oxidative stress (sub-set, n≤10)
Periodo de tiempo: Baseline, 12 weeks
|
redox sensitive fluorogenic probe fluorescence intensity for pilot study. |
Baseline, 12 weeks
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Marie-Pierre St-Onge, Columbia University
- Investigador principal: Blandine Laferrere, Columbia University
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- AAAT8914
- R01DK128154 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .